MSAC March 2023 meeting

Agenda

Applications for consideration at this meeting

1525.1 Low dose rate brachytherapy for intermediate and high-risk prostate cancer
1549 PD-L1 immunohistochemistry testing for access to pembrolizumab in combination with chemotherapy for first line treatment of triple negative breast cancer
1595.1 Closed loop upper airway stimulation for moderate to severe obstructive sleep apnoea, in patients who have failed or are intolerant to, continuous positive airway pressure therapy
1658.1 Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer for access to PBS olaparib
1700 Totally thoracoscopic exclusion of the left atrial appendage for patients with non-valvular atrial fibrillation
1701 Deep brain stimulation of the thalamus for the treatment of severe refractory epilepsy
1702 Abdominal MRI for rare genetic conditions associated with increased risk of renal tumours
1703 Detection of measurable residual disease in patients with acute lymphoblastic leukaemia
1711 Review of MBS items for subacromial decompression
1714 National Blood Authority listing for Obizur® (susoctocog alfa) for treatment of bleeding episodes with acquired Haemophilia A
1716 Germline BRCA mutation test to detect BRCA1 or BRCA2 mutations in patients with HER2- negative high risk early breast cancer to determine eligibility for PBS-listed olaparib treatment
1719 Insertion of a bioabsorbable implant for nasal airway obstruction due to lateral wall insufficiency
1722 Axicabtagene ciloleucel (Yescarta®) for relapsed or refractory large B-cell lymphoma
1724 Cardiac technical support services provided by industry employed technicians
1726 Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, for access to PBS niraparib

Consultation input

We value consultation input from individuals and organisations with an interest in an application that we are considering, including experience of the medical conditions, services or technologies being addressed by the application.

Consultation input closed Friday, 10 February 2023.

Related information

Committee:

Medical Services Advisory Committee (MSAC)

Sub menu

MSAC March 2023 meeting

Agenda

Applications for consideration at this meeting

Consultation input

Related information

Help us improve